In his new position, Dr. Landesman will be responsible for strategic leadership and managerial oversight of this practice. He will also provide consultative oversight for the firm's delivery of regulatory, quality assurance, cost optimization, and best business practices for organizations in the pharmaceutical, medical device, combination products, and biotechnology sectors.
Oriel STAT A MATRIX CEO Alan Marash noted, "Dr. Landesman's depth of industry knowledge and experience adds enormous strength to the firm's medical devices and life sciences practice. We look forward to having Paul identify new growth opportunities and shepherd the firm to the next level of knowledge leadership, customer service, performance, and professionalism."
Commenting on his new role at Oriel STAT A MATRIX, Dr. Landesman added, "Oriel STAT A MATRIX has succeeded in building a strong and well-recognized practice in the life sciences community, providing an excellent platform for future growth to meet the compliance and business requirements for our customers and the patients whom they serve."
Dr. Landesman joins Oriel STAT A MATRIX from Allergan Medical in Santa Barbara, CA, where he was a Senior Director of Quality Systems and Risk Management. He has over 30 years of experience in quality, regulatory affairs, and patient safety in the medical device, pharmaceutical, and biotech industries, and has worked with the FDA and other global regulatory bodies in a wide variety of capacities. In addition to his most recent position at Allergan, Dr. Landesman has worked with Abbott Laboratories, Hospira, and Amgen.
Dr. Landesman holds a BS in chemistry from the University of Massachusetts‒Dartmouth and a PhD in Medicinal Chemistry from the University of Buffalo. He also served as Associate Director of the Clinical Laboratories at The Ohio State University Hospitals.
About Oriel STAT A MATRIX
Since 1968, Oriel STAT A MATRIX has provided organizations with best-in-class performance improvement training and consulting—including FDA-regulated services, implementation of ISO 9000, and continual improvement methods such as Lean Six Sigma—that enhance financial results and customer satisfaction.
In 1978, US FDA regulators chose Oriel STAT A MATRIX to work with the agency in rewriting the good manufacturing practice (GMP) regulations, the precursor to the current GMP (CGMP)/quality system regulations (QSR). The firm was then selected to train FDA compliance investigators in the new regulations. Since then, Oriel STAT A MATRIX has been a global leader in implementing quality and regulatory requirements at pharmaceutical, biotechnology, and medical device companies, as well as at hospitals and other healthcare provider organizations.
Oriel STAT A MATRIX has offices in more than 18 countries and a diversified customer base that spans the globe and represents every economic sector.
For further information about Oriel STAT A MATRIX, please visit www.orielstat.com or call 732.548.0600.
SOURCE Oriel STAT A MATRIX